EMA recommends Aprea's product for orphan drug designation for AML
This article was originally published in Scrip
Executive Summary
The EMA has recommended Aprea's lead drug candidate APR-246 to the European Commission for orphan drug designation for the treatment of acute myeloid leukaemia (AML).